While GLP-1 RAs offer promising therapeutic outcomes, clinicians must address potential challenges, including gastrointestinal side effects, contraindications (e.g., pregnancy, severe GI disorders), and risks associated with improper compounding practices (48)(540)
According to FDA prescribing information, these include nausea (12-24%), diarrhea (7-23%), decreased appetite (10-19%), vomiting (2-11%), constipation (5-17%), and dyspepsia (5-9%), with rates varying by dose and indication
Before we can even talk about dosing, we have to understand what were working with
I regularly update this information based on the latest evidence around diet and GLP-1 medications
The net effect of these two actions is to improve blood sugar control
Outcomes vary, and your baseline risk factors matter a lot